Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992669 | 0.89 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991592 | 0.88 | L3MBTL1 (0.50) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991952 | 0.88 | L3MBTL1 (0.53) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991313 | 0.87 | L3MBTL1 (0.55) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991912 | 0.87 | L3MBTL1 (0.44) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991519 | 0.87 | GAA (0.50) | RAB9AMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL21991312 | 0.85 | HPGD (0.55) | L3MBTL1RAB9AMAPTKMT2AALDH1A1 | |
| SCHEMBL21991318 | 0.84 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL21991906 | 0.83 | GAA (0.47) | L3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL21991466 | 0.82 | L3MBTL1 (0.55) | L3MBTL1NPC1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.